NCT05182203

Safety and Retention Rate of the JAK and TNF Inhibitors in Rheumatoid Arthritis: a Real-life Experience

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,732 (actual)
• Sponsor: Tuen Mun Hospital · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to extract data from the Hong Kong Biologics Registry for retention rate of the JAK inhibitors in rheumatoid arthritis and review other adverse events by looking at the medical record retrospectively. These real life data are important as they cannot be provided by randomized controlled trials which are limited by the duration of observation and fixed protocols in research settings. Moreover, data will represent our local experience of the JAK inhibitors in Chinese patients with RA. The retention rate and adverse effects of the JAK inhibitors are compared with conventional TNF inhibitors.

Detailed description

This study aims to extract data from the Hong Kong Biologics Registry for retention rate of the JAK inhibitors in rheumatoid arthritis and review other adverse events by looking at the medical record retrospectively. Efficacy data and adverse events, in particular major adverse cardiovascular events (MACEs) and malignancy will be looked at and compared with the TNF inhibitors. Retention / withdrawal rates of the drugs will be studied by statistical analyses.

Conditions

• Rheumatoid Arthritis
• Drug Use

Interventions

Type	Name	Description
DRUG	biologic/targeted therapy	TNF inhibitors or the JAK inhibitors

Timeline

• Start date: 2022-03-01
• Primary completion: 2022-09-01
• Completion: 2022-10-01
• First posted: 2022-01-10
• Last updated: 2023-02-22

Locations

1 site across 1 country: China